105 related articles for article (PubMed ID: 2227154)
1. Preclinical toxicological evaluation of fostriecin, a novel anticancer antibiotic, in rats.
Susick RL; Hawkins KL; Pegg DG
Fundam Appl Toxicol; 1990 Aug; 15(2):258-69. PubMed ID: 2227154
[TBL] [Abstract][Full Text] [Related]
2. Fostriecin: a review of the preclinical data.
de Jong RS; de Vries EG; Mulder NH
Anticancer Drugs; 1997 Jun; 8(5):413-8. PubMed ID: 9215602
[TBL] [Abstract][Full Text] [Related]
3. Renal toxicity of the anticancer drug fostriecin.
de Jong RS; de Vries EG; Meijer S; de Jong PE; Mulder NH
Cancer Chemother Pharmacol; 1998; 42(2):160-4. PubMed ID: 9654117
[TBL] [Abstract][Full Text] [Related]
4. Lack of cross-resistance to fostriecin in a human small-cell lung carcinoma cell line showing topoisomerase II-related drug resistance.
de Jong S; Zijlstra JG; Mulder NH; de Vries EG
Cancer Chemother Pharmacol; 1991; 28(6):461-4. PubMed ID: 1657425
[TBL] [Abstract][Full Text] [Related]
5. Toxicity of the anticancer folate antagonist trimetrexate in rats.
Graziano MJ; Kim SN; MacDonald JR; Watkins JR
Fundam Appl Toxicol; 1992 Jan; 18(1):115-25. PubMed ID: 1534775
[TBL] [Abstract][Full Text] [Related]
6. Toxicology and Carcinogenesis Studies of Ochratoxin A (CAS No. 303-47-9) in F344/N Rats (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1989 May; 358():1-142. PubMed ID: 12695783
[TBL] [Abstract][Full Text] [Related]
7. Total synthesis of fostriecin (CI-920).
Boger DL; Ichikawa S; Zhong W
J Am Chem Soc; 2001 May; 123(18):4161-7. PubMed ID: 11457179
[TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin.
de Jong RS; Mulder NH; Uges DR; Sleijfer DT; Höppener FJ; Groen HJ; Willemse PH; van der Graaf WT; de Vries EG
Br J Cancer; 1999 Feb; 79(5-6):882-7. PubMed ID: 10070885
[TBL] [Abstract][Full Text] [Related]
9. Preclinical toxicity studies of kahalalide F, a new anticancer agent: single and multiple dosing regimens in the rat.
Brown AP; Morrissey RL; Faircloth GT; Levine BS
Cancer Chemother Pharmacol; 2002 Oct; 50(4):333-40. PubMed ID: 12357309
[TBL] [Abstract][Full Text] [Related]
10. Determination of fostriecin pharmacokinetics in plasma using high-pressure liquid chromatography assay.
Pillon L; Moore MJ; Thiessen JJ
Ther Drug Monit; 1994 Apr; 16(2):186-90. PubMed ID: 8009568
[TBL] [Abstract][Full Text] [Related]
11. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacokinetic study of fostriecin given as an intravenous bolus daily for five consecutive days.
Lê LH; Erlichman C; Pillon L; Thiessen JJ; Day A; Wainman N; Eisenhauer EA; Moore MJ
Invest New Drugs; 2004 Apr; 22(2):159-67. PubMed ID: 14739664
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of type II topoisomerase by fostriecin.
Boritzki TJ; Wolfard TS; Besserer JA; Jackson RC; Fry DW
Biochem Pharmacol; 1988 Nov; 37(21):4063-8. PubMed ID: 2847752
[TBL] [Abstract][Full Text] [Related]
14. Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance.
Glaze ER; Lambert AL; Smith AC; Page JG; Johnson WD; McCormick DL; Brown AP; Levine BS; Covey JM; Egorin MJ; Eiseman JL; Holleran JL; Sausville EA; Tomaszewski JE
Cancer Chemother Pharmacol; 2005 Dec; 56(6):637-47. PubMed ID: 15986212
[TBL] [Abstract][Full Text] [Related]
15. Preclinical toxicology of a novel polymeric antitumour agent: HPMA copolymer-doxorubicin (PK1).
Duncan R; Coatsworth JK; Burtles S
Hum Exp Toxicol; 1998 Feb; 17(2):93-104. PubMed ID: 9506260
[TBL] [Abstract][Full Text] [Related]
16. Toxicity of a quinocarmycin analog, DX-52-1, in rats and dogs in relation to clinical outcome.
Mirsalis JC; Schindler-Horvat J; Hill JR; Green CE; Mitoma C; Tomaszewski JE; Tyson CA; Donohue SJ
Cancer Chemother Pharmacol; 2003 Mar; 51(3):193-201. PubMed ID: 12655436
[TBL] [Abstract][Full Text] [Related]
17. The ovaries attenuate the aggravating effect of testosterone on glomerular injury in Adriamycin-induced nephropathy of female rats.
Sakemi T; Ohtsuka N; Tomiyoshi Y; Morito F
Kidney Blood Press Res; 1997; 20(1):44-50. PubMed ID: 9192910
[TBL] [Abstract][Full Text] [Related]
18. Nephrotoxicity of a novel antineoplastic platinum complex, nedaplatin: a comparative study with cisplatin in rats.
Uehara T; Watanabe H; Itoh F; Inoue S; Koshida H; Nakamura M; Yamate J; Maruyama T
Arch Toxicol; 2005 Aug; 79(8):451-60. PubMed ID: 15856183
[TBL] [Abstract][Full Text] [Related]
19. Response of murine small intestine to combined treatment with fostriecin and X rays.
Rao KR; Fritz-Niggli H
Br J Radiol; 1990 Apr; 63(748):286-9. PubMed ID: 2346866
[TBL] [Abstract][Full Text] [Related]
20. Renal toxicity of the antitumor drug N2-methyl-9-hydroxyellipticinium acetate in the Wistar rat.
Raguenez-Viotte G; Dadoun C; Buchet P; Ducastelle T; Fillastre JP
Arch Toxicol; 1988; 61(4):292-7. PubMed ID: 3377684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
